• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

QSAR 分析腺苷受体拮抗剂:探索吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶衍生物与人源腺苷 A(3)受体亚型结合的理化要求。

QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.

机构信息

Pharmaceutical Chemistry Division, University Institute of Pharmaceutical Sciences and UGC Center of Advanced Study in Pharmaceutical Sciences (UGC-CAS), Panjab University, Chandigarh 160 014, India.

出版信息

Bioorg Med Chem Lett. 2011 Jan 15;21(2):818-23. doi: 10.1016/j.bmcl.2010.11.094. Epub 2010 Nov 24.

DOI:10.1016/j.bmcl.2010.11.094
PMID:21163647
Abstract

Human adenosine A(3) receptor (A(3) AR) binding affinity of pyrazolotriazolopyrimidine derivatives (n=116) has been subjected to QSAR analyses using three-dimensional (shape, spatial, electronic, and molecular field) along with thermodynamic descriptors to explore the physicochemical requirements for the binding. QSAR models have been validated internally [using leave-one-out cross-validation method] and externally [using test set molecules] to ensure the predictive capacity of the models. The models suggest that shape of the substituent at N(8) position of the pyrazole ring should be optimum. Furthermore, lipophilic substituents having electronegative atoms at NH(2) group of C(5) position of the pyrimidine ring with distributed negative charge over the surface may enhance the binding affinity. Again, the carbamoylation of the NH(2) group at C(5) position of pyrimidine ring is an essential factor for binding with A(3) receptor. The QSAR models were used for the design and development of some novel thienopyrimidines which were predicted to have good affinity towards A(3) AR.

摘要

对 116 种吡唑并三嗪嘧啶衍生物的人类腺苷 A(3)受体 (A(3)AR) 结合亲和力进行了 QSAR 分析,使用三维(形状、空间、电子和分子场)以及热力学描述符来探索结合的物理化学要求。QSAR 模型已经过内部(使用留一法交叉验证方法)和外部(使用测试集分子)验证,以确保模型的预测能力。模型表明,吡唑环 N(8) 位置取代基的形状应为最佳形状。此外,嘧啶环 C(5) 位上 NH(2) 基团上带有负电性原子的亲脂性取代基,其表面上分布有负电荷,可能会增强结合亲和力。此外,嘧啶环 C(5) 位上 NH(2) 基团的氨甲酰化是与 A(3)受体结合的一个重要因素。QSAR 模型用于设计和开发一些新的噻吩并嘧啶,它们被预测对 A(3)AR 具有良好的亲和力。

相似文献

1
QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.QSAR 分析腺苷受体拮抗剂:探索吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶衍生物与人源腺苷 A(3)受体亚型结合的理化要求。
Bioorg Med Chem Lett. 2011 Jan 15;21(2):818-23. doi: 10.1016/j.bmcl.2010.11.094. Epub 2010 Nov 24.
2
QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.腺苷受体拮抗剂的定量构效关系。第3部分:探索1,2,4-三唑并[5,1-i]嘌呤衍生物与人腺苷A3受体亚型选择性结合的物理化学要求。
Bioorg Med Chem Lett. 2004 Jul 16;14(14):3705-9. doi: 10.1016/j.bmcl.2004.05.007.
3
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.新型 A2A 和 A3 腺苷受体拮抗剂 C9 和 C2 取代的吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶的设计、合成及生物学评价
J Med Chem. 2003 Mar 27;46(7):1229-41. doi: 10.1021/jm021023m.
4
Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists.阐明新型 2-芳基-吡唑并三唑嘧啶类化合物作为有效的人 A3 腺苷受体拮抗剂的药效团。
Bioorg Med Chem Lett. 2011 May 15;21(10):2898-905. doi: 10.1016/j.bmcl.2011.03.073. Epub 2011 Mar 26.
5
Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.吡咯并[3,4-e][1,2,4]三唑并[1,5-c]嘧啶作为腺苷受体拮抗剂。
Bioorg Med Chem. 2012 Jan 15;20(2):1046-59. doi: 10.1016/j.bmc.2011.11.037. Epub 2011 Dec 1.
6
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶衍生物作为腺苷受体拮抗剂。N5取代基对人A3和A2B腺苷受体亚型亲和力的影响:分子模拟研究。
J Med Chem. 2003 Sep 25;46(20):4287-96. doi: 10.1021/jm030852k.
7
Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.基于靶点和配体的联合药物设计方法作为定义人 A3 腺苷受体拮抗剂新型 3D 药效团模型的工具:吡唑并[4,3-e]1,2,4-三唑并[1,5-c]嘧啶衍生物作为关键研究。
J Med Chem. 2005 Jan 13;48(1):152-62. doi: 10.1021/jm049662f.
8
Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.使用集成支持向量机(SVM)方法结合选择性和亲和力预测:一种区分人腺苷A(2A)和A(3)受体吡唑并三唑并嘧啶拮抗剂结合位点的替代工具。
Bioorg Med Chem. 2009 Jul 15;17(14):5259-74. doi: 10.1016/j.bmc.2009.05.038. Epub 2009 May 21.
9
Affinity prediction on A3 adenosine receptor antagonists: the chemometric approach.A3 腺苷受体拮抗剂的亲和力预测:化学计量学方法。
Bioorg Med Chem. 2011 Nov 15;19(22):6853-9. doi: 10.1016/j.bmc.2011.09.032. Epub 2011 Sep 22.
10
Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.嘧啶衍生物作为强效和选择性的 A3 腺苷受体拮抗剂。
J Med Chem. 2011 Jan 27;54(2):457-71. doi: 10.1021/jm100843z. Epub 2010 Dec 27.

引用本文的文献

1
Advances in pyrazolo[1,5-]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment.吡唑并[1,5 - ]嘧啶的研究进展:合成及其在癌症治疗中作为蛋白激酶抑制剂的作用
RSC Adv. 2025 Feb 5;15(5):3756-3828. doi: 10.1039/d4ra07556k. eCollection 2025 Jan 29.
2
Current Understanding of the Role of Adenosine Receptors in Cancer.目前对腺苷受体在癌症中的作用的认识。
Molecules. 2024 Jul 26;29(15):3501. doi: 10.3390/molecules29153501.
3
Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors.
乙酰胆碱酯酶抑制剂的分子对接和受体特异性 3D-QSAR 研究。
Mol Divers. 2012 Nov;16(4):803-23. doi: 10.1007/s11030-012-9394-x. Epub 2012 Sep 21.